Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01101100 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
A Phase 2 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT01101100: Clinical Trial Phase 2 study, sponsored by Bausch Health Americas.
NCT01101100 is a Phase 2 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 181 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01101100, a Phase 2 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.
Primary Outcome
Percentage of participants with a static physician's global assessment (sPGA) of clear (0) or clear/almost clear (0 or 1)
Interventions
- DRUG AMG 827
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2010-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Why NCT01101100 stopped before completion
NCT01101100 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 1 intervention - of which AMG 827 is the first listed.
NCT01101100 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01101100 about?
NCT01101100 is a clinical study titled "Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis". This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.
What is the current status of trial NCT01101100?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2010-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01101100?
The interventions under investigation include: AMG 827 (DRUG).
Who is sponsoring clinical trial NCT01101100?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01101100's enrollment target sits among peer trials
181 365th of 2000 higher than 1,636 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia